Bosutinib/Strong CYP3A4 Inhibitors that Prolong QT Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your body processes your bosutinib.
What might happen:
The amount of bosutinib in your blood may increase and cause more side effects than expected. Some expected side effects may be more severe than expected.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicine or the timing of your medicine.Let your doctor know right away if you experience nausea, vomiting, abdominal pain (especially in the right upper area of your abdomen), yellowing of the eyes or skin, dark urine, itching, loss of appetite, fever, any unusual bleeding, chest pain or pressure, shortness of breath, coughing, swelling of the ankles/legs, rapid/fast/irregular heartbeat, dizziness, loss of consciousness,or if you gain more than 5 pounds in 24 hours.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. May, 2021.
- 2.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 3.Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther 2012 Sep;34(9):2011-9.e1.
- 4.Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011 Dec;51(12):1721-7.
- 5.Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc Prolongation Among Cancer Patients Treated with Tyrosine Kinase Inhibitors. Int J Cancer. 2020 May 25.
- 6.USDepartment of Health and Human Services Food and Drug Administration. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: https://www.fda.gov/media/71372/download October, 2005.
- 7.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 8.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.